Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Osteosarcoma Gene Therapy
Researchers from St. Vincent's Hospital, Department of Orthopaedics report on findings in osteosarcoma gene therapy
August 19th, 2008
Researchers detail in 'c-Jun knockdown sensitizes osteosarcoma to doxorubicin,' new data in osteosarcoma. "The oncogene c-Jun has been found to be up-regulated in a variety of cancers, including osteosarcoma. Doxorubicin is a frontline chemotherapeutic against osteosarcoma, but is limited by toxicity," scientists in Fitzroy, Australia report. "DNAzymes are oligonucleotides capable of specific catalysis of target mRNA. A biocompatible c-Jun DNAzyme nanoparticle formulated from chitosan regressed the growth and metastasis of pre-established tumors, especially in combination with doxorubicin. In vitro data confirmed that c-Jun knockdown chemosensitized these cells to...
Source: Cancer Weekly (2008-08-19)
|
